Accelerating Pre-Clinical Research with Precision Proteomics

From cell models to organoids, 3D cultures, animal models and non-human primates – Sciomics supports every step of pre-clinical development with our Precision Proteomics Platform.
Gain deeper molecular insights, identify the most promising drug candidates, and accelerate your pre-clinical research with protein and post-translational modification analyses.

How Pharma Partners use our Proteomics

  • Dose optimisation: define optimal dose levels and assess drug effects over time
  • Safety & Toxicology: detect toxicity markers, organ damage, inflammation, cytokine activation
  • Mechanism of Action: uncover pathways driving efficacy and adverse events (e.g. complement activation, cytokine storm)
  • Immunogenicity Assessment: distinguish immunogenic vs. non-immunogenic responses
  • Resistance Mechanisms: identify resistance pathways and compensatory signalling networks
  • Target Synergies: evaluate molecular interactions for combination therapies
  • Compound Benchmarking: select the best candidate and compare against competitors
Proteomics Illustration
scioDiscover_Applications

Sciomics Microarrays Supporting your Pre-Clinical Research

Sciomics provides four specialized microarray assays – scioPhospho, scioDiscover, scioCD, and scioCyto – tailored to the needs of pharma partners in pre-clinical research.

scioPhospho

Challenges in Pre-Clinical Research - and how Sciomics solves them

Preclinical Graphic

Flexible Precision Protein Profiling using Diverse Sample Types

Our flexible proteomics platform delivers robust and reproducible protein profiling across diverse sample types – from human and murine to organoid systems – even with minimal sample amounts. Click here for further information.

Sample Types

Supporting Pre-Clinical Research across Key Disease Areas

Sciomics has supported numerous pre-clinical research projects across diverse disease areas. Our Precision Proteomics platforms provide valuable insights into molecular mechanisms, safety, and efficacy, helping pharma partners advance drug development in multiple therapeutic fields:

  • Neurodegenerative diseases (Alzheimer‘s, Parkinson‘s, FTD, Lewy Body diseases)
  • Oncology
  • Ageing research
  • Cardiovascular diseases
  • Skin diseases (Atopic dermatitis, Psoriasis, Akne inversa)
  • Inflammatory diseases (IBD, Crohn‘s disease)
  • Kidney diseases
  • Organ damage and failure

Testimonials

PD Dr. med. Mascha O. Fiedler-Kalenka and Dr. med. Benjamin Seybold

Heidelberg University Hospital, Department of Anesthesiology, Heidelberg, GermanyGerman Center for Lung Research (DZL), Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany

"From the very beginning, working with the friendly and highly competent team at Sciomics was both professional and refreshingly straightforward. We particularly valued their openness to our specific research questions and the expert support they provided in planning and interpreting our exploratory cytokine analysis in a preclinical lung injury model. Communication was always on equal footing, enriched by Sciomics’ deep expertise, which also sparked new ideas for future projects."

Product: scioCD

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

BACK_TO_TOP